PFE · Earnings call · 2026Q3T · Full report

Migraine Product Development

PFIZER INC · 2026-11-03 · Importance 52 · Surprise 56

Biohaven grew 33% operationally in the quarter, with management citing underlying demand and commercial execution. Pfizer said it leads the oral CGRP class in the U.S. and is working to extend that position internationally. Management noted growth as access expanded in the U.K., Italy, and Japan, and said adoption is strong where access is available despite competition in the category.

Key facts

• Pfizer leads the oral CGRP class in the U.S. and is working to extend that position internationally.
• Pfizer cited international oral CGRP growth in the U.K., Italy, and Japan as more patients gained access to treatment.